Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Revenue
Other revenue 940
Total revenue 940
Operating expenses:    
Research and development, net of reimbursements 7,849 4,369
General and administrative 3,735 1,735
Total operating expenses 11,584 6,104
Loss from operations (11,584) (5,164)
Other income:    
Interest income - net 547 35
Total other income 547 35
Net loss $ (11,037) $ (5,129)
Net loss per share of common stock – basic and diluted (in Dollars per share) $ (0.43) $ (0.23)
Weighted average shares of common stock outstanding – basic and diluted (in Shares) 25,696,623 22,143,974